JP2011503063A5 - - Google Patents

Download PDF

Info

Publication number
JP2011503063A5
JP2011503063A5 JP2010533098A JP2010533098A JP2011503063A5 JP 2011503063 A5 JP2011503063 A5 JP 2011503063A5 JP 2010533098 A JP2010533098 A JP 2010533098A JP 2010533098 A JP2010533098 A JP 2010533098A JP 2011503063 A5 JP2011503063 A5 JP 2011503063A5
Authority
JP
Japan
Prior art keywords
medicament
cancer
compound
pharmaceutically acceptable
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010533098A
Other languages
English (en)
Japanese (ja)
Other versions
JP5645667B2 (ja
JP2011503063A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/012539 external-priority patent/WO2009061446A1/en
Publication of JP2011503063A publication Critical patent/JP2011503063A/ja
Publication of JP2011503063A5 publication Critical patent/JP2011503063A5/ja
Application granted granted Critical
Publication of JP5645667B2 publication Critical patent/JP5645667B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010533098A 2007-11-08 2008-11-07 増殖性疾患を治療するための、N−(5−tert−ブチル−イソキサゾール−3−イル)−N’−{4−[7−(2−モルホリン−4−イル−エトキシ)イミダゾ[2,l−b][l,3]ベンゾチアゾール−2−イル]フェニル}尿素の投与方法 Active JP5645667B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US258307P 2007-11-08 2007-11-08
US61/002,583 2007-11-08
US580307P 2007-12-07 2007-12-07
US61/005,803 2007-12-07
US9867608P 2008-09-19 2008-09-19
US61/098,676 2008-09-19
US11206008P 2008-11-06 2008-11-06
US61/112,060 2008-11-06
PCT/US2008/012539 WO2009061446A1 (en) 2007-11-08 2008-11-07 Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014120238A Division JP2014221765A (ja) 2007-11-08 2014-06-11 増殖性疾患を治療するための、N−(5−tert−ブチル−イソキサゾール−3−イル)−N’−{4−[7−(2−モルホリン−4−イル−エトキシ)イミダゾ[2,l−b][l,3]ベンゾチアゾール−2−イル]フェニル}尿素の投与方法

Publications (3)

Publication Number Publication Date
JP2011503063A JP2011503063A (ja) 2011-01-27
JP2011503063A5 true JP2011503063A5 (https=) 2011-12-22
JP5645667B2 JP5645667B2 (ja) 2014-12-24

Family

ID=40262072

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010533098A Active JP5645667B2 (ja) 2007-11-08 2008-11-07 増殖性疾患を治療するための、N−(5−tert−ブチル−イソキサゾール−3−イル)−N’−{4−[7−(2−モルホリン−4−イル−エトキシ)イミダゾ[2,l−b][l,3]ベンゾチアゾール−2−イル]フェニル}尿素の投与方法
JP2014120238A Pending JP2014221765A (ja) 2007-11-08 2014-06-11 増殖性疾患を治療するための、N−(5−tert−ブチル−イソキサゾール−3−イル)−N’−{4−[7−(2−モルホリン−4−イル−エトキシ)イミダゾ[2,l−b][l,3]ベンゾチアゾール−2−イル]フェニル}尿素の投与方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014120238A Pending JP2014221765A (ja) 2007-11-08 2014-06-11 増殖性疾患を治療するための、N−(5−tert−ブチル−イソキサゾール−3−イル)−N’−{4−[7−(2−モルホリン−4−イル−エトキシ)イミダゾ[2,l−b][l,3]ベンゾチアゾール−2−イル]フェニル}尿素の投与方法

Country Status (18)

Country Link
US (1) US7968543B2 (https=)
EP (2) EP2596795A1 (https=)
JP (2) JP5645667B2 (https=)
KR (2) KR101578481B1 (https=)
CN (1) CN101835472A (https=)
AR (1) AR069244A1 (https=)
AU (1) AU2008325141B2 (https=)
CA (1) CA2696807C (https=)
CY (1) CY1114853T1 (https=)
DK (1) DK2205244T3 (https=)
ES (1) ES2436266T3 (https=)
HR (1) HRP20131083T1 (https=)
MX (1) MX2010002396A (https=)
PL (1) PL2205244T3 (https=)
PT (1) PT2205244E (https=)
SI (1) SI2205244T1 (https=)
TW (1) TW200924756A (https=)
WO (1) WO2009061446A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101449057B1 (ko) * 2006-03-17 2014-10-10 암비트 바이오사이언시즈 코포레이션 질환 치료용 이미다졸로티아졸 화합물
EP2201018B1 (en) * 2007-09-19 2016-03-16 Ambit Biosciences Corporation Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-ý7-(2-morpholin-4-yl-ethoxy)imidazoý2,1-b¨ý1,3¨benzothiazol-2-yl¨phenyl}urea, compositions thereof, and uses therewith
CA2755976C (en) 2009-03-23 2020-04-07 Ambit Biosciences Corporation Methods of treatment using combination therapy
SMT202000092T1 (it) * 2009-05-14 2020-05-08 Ambit Biosciences Corp Formulazione essiccata a spruzzo o liofilizzata di ac220
WO2011056939A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Process for the preparation of imidazo[2,1-b][1,3]benzothiazole derivatives
HUE045270T2 (hu) 2010-01-05 2019-12-30 Inst Nat Sante Rech Med FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
AR081776A1 (es) 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
CN103172648B (zh) * 2011-12-20 2016-05-25 上海迪诺医药科技有限公司 三杂环衍生物、制备方法及应用
JP6116847B2 (ja) * 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションAmbit Biosciences Corporation シクロデキストリンとの混合体を含有する錠剤
CN104513259B (zh) * 2013-09-26 2017-06-16 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
BR112017002001B1 (pt) * 2014-07-31 2022-10-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compostos e composição farmacêutica
SG10202001034PA (en) 2014-12-22 2020-04-29 Genzyme Corp Methods of culturing a mammalian cell
CA2976752C (en) 2015-02-20 2019-12-17 Daiichi Sankyo Company, Limited Method for treating cancer by combined use
JP6793401B2 (ja) * 2015-03-11 2020-12-02 国立研究開発法人理化学研究所 難治性白血病治療薬
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
JP2020519665A (ja) 2017-05-17 2020-07-02 アンセルム(アンスティテュト ナショナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル) オピオイドによる痛みの処置を改善する為のflt3阻害剤
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
WO2021180008A1 (zh) * 2020-03-11 2021-09-16 暨南大学 含脲结构的三芳环化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233906A (en) * 1880-11-02 Combined stirrer and thermometer
US233903A (en) * 1880-11-02 Velocipede
US994635A (en) * 1911-01-10 1911-06-06 Harry C Buhoup Car-truck.
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
KR101449057B1 (ko) * 2006-03-17 2014-10-10 암비트 바이오사이언시즈 코포레이션 질환 치료용 이미다졸로티아졸 화합물
EP2201018B1 (en) * 2007-09-19 2016-03-16 Ambit Biosciences Corporation Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-ý7-(2-morpholin-4-yl-ethoxy)imidazoý2,1-b¨ý1,3¨benzothiazol-2-yl¨phenyl}urea, compositions thereof, and uses therewith

Similar Documents

Publication Publication Date Title
JP2011503063A5 (https=)
AU2023380159A1 (en) Pharmaceutical combinations and uses thereof
CN102421429B (zh) 癌症治疗用选择性ep4受体拮抗物质
JP2006503919A5 (https=)
WO2010031265A1 (zh) 用于治疗增生性疾病的药物组合物
JP6029808B2 (ja) 併用療法における(+)−1,4−ジヒドロ−7−[(3s,4s)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸の使用方法
JP2014530852A5 (https=)
TW202333675A (zh) 用於治療癌症之組合療法之用途
JP2018503610A5 (https=)
CN103533940A (zh) 治疗晚期实体瘤的方法
JP5514123B2 (ja) 卵巣癌を治療するための、パクリタキセルを含む配合剤
JP2015517523A5 (https=)
CN102065865A (zh) 多发性骨髓瘤治疗
CN115025090A (zh) 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒
JP2025160200A (ja) クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬
JP2016520665A (ja) Mps−1キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ
KR20250079033A (ko) Kras 억제제와 조합된 pim 키나제 억제제
CN112584834B (zh) 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物
CN101357134A (zh) 抗肿瘤效果增强剂和抗肿瘤剂
JP2016502540A5 (https=)
JP2016501884A5 (https=)
JP2023509191A (ja) 癌を治療するための組み合わせ療法
JP2020528418A (ja) BET阻害剤及びBcl−2阻害剤を用いた併用療法
JP2022509257A5 (https=)
JP7707329B2 (ja) クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬